Neurobiology of Migraine

Migraine is a complex neurological disorder, not simply a severe headache. Modern neuroscience has substantially clarified its mechanisms, enabling targeted therapeutics that have transformed treatment outcomes.

  • Cortical spreading depression (CSD): A wave of neuronal and glial depolarization spreading across the cortex at ~3mm/min, followed by sustained suppression — the neurophysiological correlate of migraine aura. CSD activates trigeminal pain pathways
  • Trigeminovascular system: CSD and other triggers activate trigeminal nerve endings in meningeal vessels, releasing inflammatory neuropeptides — particularly CGRP (calcitonin gene-related peptide), the central mediator of migraine pain and vasodilation
  • CGRP: Released during migraine attacks; levels normalize with triptan treatment and remain elevated in chronic migraine; blocking CGRP or its receptor is the mechanism of the newest and most effective preventive medications
  • Central sensitization: Repeated migraine attacks sensitize central trigeminal neurons, lowering the threshold for subsequent attacks — the basis of migraine chronification and medication overuse headache
  • Genetics: Heritability ~50%; multiple susceptibility loci identified; familial hemiplegic migraine has rare monogenic causes (CACNA1A, ATP1A2)

Types & Phases of Migraine

Migraine without aura — most common (75%); unilateral throbbing headache, nausea/vomiting, photophobia/phonophobia, lasting 4–72 hours

Migraine with aura — 25% of migraineurs; reversible focal neurological symptoms (visual zigzag lines, scotomas, sensory changes) preceding headache by 20–60 minutes

Chronic migraine — 15+ headache days/month for 3+ months, with 8+ migraine features; affects ~2% of adults; often involves medication overuse headache (MOH)

The four phases:

  • Prodrome (hours-days before): Fatigue, food cravings, neck stiffness, mood changes, yawning — early warning signs that trigger intervention opportunity
  • Aura (if present): Focal neurological symptoms lasting 20–60 min; fully reversible
  • Headache phase: Moderate-severe unilateral throbbing pain; worsened by movement; nausea; photo/phonophobia; 4–72 hours
  • Postdrome: Hours of fatigue, cognitive fog, mood changes after headache resolution — the "migraine hangover"

Trigger Identification & Management

Migraine triggers lower the threshold for attack in already-susceptible individuals rather than causing migraine directly. Common triggers include:

  • Sleep disruption: Both too little and too much sleep; irregular sleep patterns are among the most consistent triggers
  • Hormonal changes: Estrogen fluctuation around menstruation is the most common trigger in women (menstrual migraine); oral contraceptives can worsen or improve migraine
  • Stress and stress let-down: Both acute stress and the relaxation after sustained stress (weekend migraine) are triggers
  • Dehydration: Even mild dehydration lowers the threshold; consistent hydration is protective
  • Skipping meals / blood glucose fluctuation: Fasting and irregular eating patterns are common triggers
  • Dietary: Alcohol (especially red wine — histamine, tyramine), caffeine withdrawal, aged cheeses (tyramine), processed meats (nitrates), MSG — individual variation is high; food diaries more useful than universal restriction
  • Sensory: Bright lights, flickering screens, strong smells, loud noise, weather changes (barometric pressure)
  • Trigger stacking: Individual triggers may not cause migraine; multiple simultaneous triggers (poor sleep + stress + alcohol) often do — understanding the threshold model helps explain attack variability

Acute (Abortive) Treatment Evidence

  • Triptans (sumatriptan, rizatriptan, eletriptan): First-line specific migraine acute treatment; 5-HT1B/1D receptor agonists; reduce CGRP release and cause vasoconstriction; 60–70% achieve pain freedom at 2 hours vs 20–30% placebo; nasal/injectable formulations faster for rapid onset; contraindicated in cardiovascular disease
  • Gepants (ubrogepant, rimegepant): CGRP receptor antagonists; oral; comparable efficacy to triptans without vasoconstrictive risk; no medication overuse headache risk; rimegepant also approved for prevention
  • Ditans (lasmiditan): 5-HT1F agonist; no vasoconstriction; effective in cardiovascular patients; CNS side effects (dizziness, sedation); cannot drive for 8h after
  • NSAIDs (ibuprofen, naproxen, aspirin): Effective for mild-moderate migraine; often combined with antiemetics; aspirin 900mg + metoclopramide comparable to sumatriptan in some trials
  • Antiemetics (metoclopramide, prochlorperazine): Treat nausea and enhance absorption of oral medications; IV prochlorperazine effective for ED management of severe migraine
  • Critical timing: All acute treatments are most effective when taken early in the attack — at first sign of headache, before central sensitization develops

Preventive Treatment Evidence

Prevention is indicated when migraines occur 4+ days/month, significantly impair function, or when acute treatments are overused:

  • CGRP monoclonal antibodies — erenumab (Aimovig), fremanezumab (Ajovy), galcanezumab (Emgality): Target CGRP or its receptor; monthly or quarterly injections; reduce migraine days by 50%+ in ~50% of patients; excellent safety profile; most significant migraine prevention advance in decades; effective in previously treatment-refractory patients
  • Topiramate: Anticonvulsant; strong evidence for migraine prevention (50% reduction in ~40% of patients); weight loss side effect; cognitive dulling ("dopamax") limits tolerability
  • Beta-blockers (propranolol, metoprolol): Long-established first-line preventives; 40–50% reduction in attack frequency; well-tolerated; useful in patients with comorbid hypertension or anxiety
  • Amitriptyline: Tricyclic antidepressant; strong evidence for migraine and tension-type headache prevention; useful for comorbid depression, insomnia, or chronic pain
  • Valproate: Anticonvulsant with strong migraine prevention evidence; teratogenic — not used in women of childbearing age
  • Botulinum toxin (Botox): FDA-approved for chronic migraine (15+ headache days/month); quarterly injections of 155 units across 31 sites; reduces monthly headache days by 8–9 in trials

Lifestyle & Nutritional Prevention

  • Magnesium: Multiple RCTs and meta-analyses support magnesium supplementation for migraine prevention; deficiency is found in ~50% of migraineurs; 400–600mg magnesium oxide or glycinate/day reduces attack frequency by ~30–40%; IV magnesium sulfate effective for acute migraine in ED settings
  • Riboflavin (Vitamin B2): 400mg/day shown in RCTs to reduce migraine frequency by ~50%; improves mitochondrial energy metabolism in a neurologically vulnerable population; few side effects; orange urine is benign
  • Coenzyme Q10 (CoQ10): 300mg/day shown in RCTs to reduce migraine frequency; mitochondrial cofactor; low side effect profile; particularly useful as adjunct
  • Melatonin: 3mg before bedtime shown comparable to amitriptyline for migraine prevention in one RCT; regulates the sleep-wake cycle disruptions that trigger migraine
  • Regular sleep schedule: Consistent bedtime and wake time is one of the most consistently evidence-supported behavioral interventions; irregular sleep is a major trigger
  • Aerobic exercise: Regular moderate aerobic exercise (3x/week, 40 min) shown in RCT to be as effective as topiramate and relaxation therapy for migraine prevention; reduces attack frequency and severity
  • Hydration: Maintaining consistent hydration reduces trigger susceptibility; 2.5L/day target in migraineurs

Frequently Asked Questions

For acute treatment, triptans (sumatriptan, rizatriptan, eletriptan) are the most evidence-supported specific migraine treatments — achieving pain freedom in 60–70% at 2 hours. For prevention, CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab) are the most significant recent advance, reducing migraine days by 50%+ in about half of patients. The best approach combines acute medication, preventive treatment if indicated, and lifestyle optimization.

Common triggers include sleep disruption, hormonal fluctuations (especially perimenstrual estrogen drops), stress and post-stress relaxation, dehydration, skipped meals, alcohol (particularly red wine), caffeine withdrawal, bright lights, and barometric pressure changes. Triggers are highly individual and work cumulatively — multiple simultaneous triggers are more likely to cause an attack than any single trigger alone. A migraine diary helps identify personal patterns.

Yes — magnesium has consistent RCT and meta-analysis evidence for migraine prevention. Magnesium deficiency is found in approximately 50% of migraineurs, and supplementation (400–600mg/day) reduces attack frequency by 30–40% in multiple trials. It is recommended as a first-line preventive supplement in the American Headache Society guidelines. Magnesium glycinate or oxide are the most studied forms.

CGRP (calcitonin gene-related peptide) is the primary neuropeptide mediating migraine pain and vasodilation. Two classes target this pathway: CGRP monoclonal antibodies (monthly or quarterly injections — erenumab, fremanezumab, galcanezumab) for prevention, and gepants (ubrogepant, rimegepant — oral pills) for acute treatment and prevention. These are the most significant advances in migraine treatment in decades and work in patients who have failed multiple prior treatments.

Yes — regular aerobic exercise has strong evidence for migraine prevention. A Swedish RCT found 40 minutes of cycling 3 times per week was as effective as topiramate (a prescription preventive) and relaxation therapy for reducing migraine frequency. The protective mechanism likely involves serotonin regulation, endorphin release, and improved sleep quality. Importantly, exercise during a prodrome can sometimes trigger an attack — timing matters.

Research Summary

Migraine is a neurological disorder with strong evidence for both acute and preventive treatments. CGRP-targeting therapies represent a paradigm shift; magnesium, riboflavin, and exercise are well-supported adjuncts.

  • Evidence strength: Strong (5/5)
  • Global burden: 1 billion affected; 2nd leading cause of disability
  • Best acute treatment: Triptans (60–70% pain freedom at 2h)
  • Best preventive advance: CGRP antibodies (50%+ reduction in ~50% of patients)
  • Evidence-based supplements: Magnesium 400–600mg, Riboflavin 400mg, CoQ10 300mg
  • Lifestyle: Regular aerobic exercise as effective as topiramate in RCT
⚠️ Medical Disclaimer: This content is for informational purposes only and is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before making health decisions.

References

All studies cited are peer-reviewed. DOI and PubMed links open in a new tab.

  1. 1. Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S (2017). Pathophysiology of Migraine: A Disorder of Sensory Processing. Physiological Reviews, 97(2), 553–622. doi:10.1152/physrev.00034.2015 PMID:28179494
  2. 2. Dodick DW, Turkel CC, DeGryse RE, et al. (2010). OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache, 50(6), 921–936. doi:10.1111/j.1526-4610.2010.01678.x PMID:20487038
  3. 3. Tepper SJ (2018). Anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: Update on a Previous Review After the American Headache Society 60th Scientific Meeting, San Francisco, June 2018. Headache, 58 Suppl 3, 276–290. doi:10.1111/head.13417 PMID:30242836
  4. 4. Schrader H, Stovner LJ, Helde G, Sand T, Bovim G (2001). Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study. BMJ, 322(7277), 19–22. doi:10.1136/bmj.322.7277.19 PMID:11141153
  5. 5. Varkey E, Cider A, Carlsson J, Linde M (2011). Exercise as migraine prophylaxis: a randomized study using relaxation and topiramate as controls. Cephalalgia, 31(14), 1428–1438. doi:10.1177/0333102411419681 PMID:21890526
  6. 6. Peikert A, Wilimzig C, Kohne-Volland R (1996). Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalalgia, 16(4), 257–263. doi:10.1046/j.1468-2982.1996.1604257.x PMID:8792038
  7. 7. Schoenen J, Jacquy J, Lenaerts M (1998). Effectiveness of high-dose riboflavin in migraine prophylaxis: a randomized controlled trial. Neurology, 50(2), 466–470. doi:10.1212/wnl.50.2.466 PMID:9484373
  8. 8. Sándor PS, Di Clemente L, Coppola G, et al. (2005). Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology, 64(4), 713–715. doi:10.1212/01.WNL.0000151975.03598.ED PMID:15728298